Article

Caveolin-1 promotes resistance to chemotherapy-induced apoptosis in Ewing's sarcoma cells by modulating PKCalpha phosphorylation.

Institut d'Investigació Biomédica de Bellvitge, Centre d'Oncología Molecular, L'Hospitalet de Llobregat, Barcelona, Spain.
International Journal of Cancer (Impact Factor: 5.01). 08/2009; 126(2):426-36. DOI: 10.1002/ijc.24754
Source: PubMed

ABSTRACT Caveolin-1 (CAV1) has been implicated in the regulation of several signaling pathways and in oncogenesis. Previously, we identified CAV1 as a key determinant of the oncogenic phenotype and tumorigenic activity of cells from tumors of the Ewing's Sarcoma Family (ESFT). However, the possible CAV1 involvement in the chemotherapy resistance commonly presented by an ESFT subset has not been established to date. This report shows that CAV1 expression determines the sensitivity of ESFT cells to clinically relevant chemotherapeutic agents. Analyses of endogenous CAV1 levels in several ESFT cells and ectopic CAV1 expression into ESFT cells expressing low endogenous CAV1 showed that the higher the CAV1 levels, the greater their resistance to drug treatment. Moreover, results from antisense- and shRNA-mediated gene expression knockdown and protein re-expression experiments demonstrated that CAV1 increases the resistance of ESFT cells to doxorubicin (Dox)- and cisplatin (Cp)-induced apoptosis by a mechanism involving the activating phosphorylation of PKCalpha. CAV1 knockdown in ESFT cells led to decreased phospho(Thr(638))-PKCalpha levels and a concomitant sensitization to apoptosis, which were reversed by CAV1 re-expression. These results were recapitulated by PKCalpha knockdown and re-expression in ESFT cells in which CAV1 was previously knocked down, thus demonstrating that phospho(Thr(638))-PKCalpha acts downstream of CAV1 to determine the sensitivity of ESFT cells to chemotherapeutic drugs. These data, along with the finding that CAV1 and phospho(Thr(638))-PKCalpha are co-expressed in approximately 45% of ESFT specimens tested, imply that targeting CAV1 and/or PKCalpha may allow the development of new molecular therapeutic strategies to improve the treatment outcome for patients with ESFT.

0 Followers
 · 
106 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Interlocking gene mutations, epigenetic alterations and microenvironmental features perpetuate tumor development, growth, infiltration and spread. Consequently, intrinsic and acquired therapy resistance arises and presents one of the major goals to solve in oncologic research today. Among the myriad of microenvironmental factors impacting on cancer cell resistance, cell adhesion to the extracellular matrix (ECM) has recently been identified as key determinant. Despite the differentiation between cell adhesion-mediated drug resistance (CAMDR) and cell adhesion-mediated radioresistance (CAMRR), the underlying mechanisms share great overlap in integrin and focal adhesion hub signaling and differ further downstream in the complexity of signaling networks between tumor entities. Intriguingly, cell adhesion to ECM is per se also essential for cancer cells similar to their normal counterparts. However, based on the overexpression of focal adhesion hub signaling receptors and proteins and a distinct addiction to particular integrin receptors, targeting of focal adhesion proteins has been shown to potently sensitize cancer cells to different treatment regimes including radiotherapy, chemotherapy and novel molecular therapeutics. In this review, we will give insight into the role of integrins in carcinogenesis, tumor progression and metastasis. Additionally, literature and data about the function of focal adhesion molecules including integrins, integrin-associated proteins and growth factor receptors in tumor cell resistance to radio- and chemotherapy will be elucidated and discussed.
    Seminars in Cancer Biology 08/2014; 31. DOI:10.1016/j.semcancer.2014.07.009 · 9.14 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Dedication: To the memory of Alba Pérez. Cell death can occur through different mechanisms, defined by their nature and physiological implications. Correct assessment of cell death is crucial for cancer therapy success. Sarcomas are a large and diverse group of neoplasias from mesenchymal origin. Among cell death types, apoptosis is by far the most studied in sarcomas. Albeit very promising in other fields, regulated necrosis and other cell death circumstances (as so-called " autophagic cell death " or " mitotic catastrophe ") have not been yet properly addressed in sarcomas. Cell death is usually quantified in sarcomas by unspecific assays and in most cases the precise sequence of events remains poorly characterized. In this review, our main objective is to put into context the most recent sarcoma cell death findings in the more general landscape of different cell death modalities.
    Frontiers in Oncology 05/2015; 5:82. DOI:10.3389/fonc.2015.00082
  • [Show abstract] [Hide abstract]
    ABSTRACT: Caveolin-1 is a transmembrane protein and essential structural constituent of the caveolae membrane. Caveolin-1 has been involved in multiple cellular functions and oncogenesis. To investigate the roles of caveolin-1, stable transfectants were established in PANC1 pancreatic adenocarcinoma cells which had up-regulated caveolin-1 expression. The plasmid pCI-neo-cav-1 and its corresponding empty vector (pCI-neo) were transfected into PANC1 cell lines. The expression of caveolin-1 in these three cell lines was determined by RT-PCR and Western blot. Cell cycle phase distribution was determined by flow cytometry. The colony formation ability of tumor cells was detected by anchorage-independent growth assay. Cell migration and invasion were assayed in MilliCell chambers. Xenograft tumor models in nude mice were developed. Immunohistochemistry was used to characterize Ki-67 levels in residual tumors, and apoptosis was evaluated by TUNEL technique. Caveolin-1 overexpression inhibited PANC1 cell proliferation by arresting the cell cycle in the G0/G1 phases and also markedly reduced the capacity of the cells to form colonies in soft agar. Additionally, caveolin-1 overexpression dramatically inhibited cells to invade and migrate. Importantly, in vivo experiments demonstrated that overexpression of caveolin-1 resulted in significant growth inhibition of the xenograft pancreatic tumors. Immunohistochemistry analysis demonstrated both a marked decrease in the number of proliferating tumor cells and an increase in the number of apoptotic tumor cells in PANC1/cav-1 xenograft tumors. The results provide an initial demonstration that caveolin-1 can function as a tumor suppressor rather than as a tumor promoter in PANC1 cells.
    Progress in Biochemistry and Biophysics 12/2012; 38(12):1121-1131. DOI:10.3724/SP.J.1206.2011.00168 · 0.29 Impact Factor

Full-text (2 Sources)

Download
48 Downloads
Available from
Jun 4, 2014